Skip to main content
. Author manuscript; available in PMC: 2016 Feb 9.
Published in final edited form as: J Clin Lipidol. 2014 Oct 13;9(1):93–102. doi: 10.1016/j.jacl.2014.09.013

Figure 1.

Figure 1

Between-group differences in mean percent change from baseline for whole plasma lipid/apolipoprotein (apo) concentrations as assayed by standard techniques in the overall analysis population and subgroups defined by median baseline triglyceride (TG) value (≤ and >154 mg/dL). (A–C) Between-group differences for the placebo vs anacetrapib alone, placebo vs atorvastatin alone, and atorvastatin alone vs atorvastatin + anacetrapib treatment comparisons, respectively. Negative values favor anacetrapib alone or atorvastatin alone vs placebo or atorvastatin + anacetrapib vs atorvastatin alone except for high-density lipoprotein cholesterol (HDL-C) and apolipoprotein AI (apoAI). HDL-C, high-density lipoprotein cholesterol; Lp(a), lipoprotein a; TC, total cholesterol.